Etude CC-486-MDS-006 : étude randomisée de phase 2 visant à évaluer l’efficacité et la sécurité d’une association d’azacitidine et de durvalumab chez des patients ayant un syndrome myélodysplasique. [essai clos aux inclusions] Les syndromes myélodysplasiques (SMD) forment un ensemble de maladies caractérisées par la production insuffisante de cellules sanguines matures saines par la moelle osseuse. Les cellules sanguines im...

• Pays France
• Organes Syndromes myélodysplasiques (SMD)
• Spécialités Chimiothérapie, Immunothérapie - Vaccinothérapie

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects with Acute Myeloid Leukemia (AML) no longer experiences symptoms of the disease The primary objective of the study is to evaluiate whether maintenance therapy with oral azacitidine improves OS compared with placebo in subjects with AML, age ≥55 years, who have achieved first CR o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn’s disease To evaluate the efficacy of GED-0301 compared with placebo on clinical activity at 12 Weeks, in subjects with active Crohn’s disease (CD).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi center study to assess the safety and efficacy of nab-paclitaxel with CC-486, nab-paclitaxel with MEDI4736 and nab-paclitaxel alone as 2nd/3rd line treatment in subjects with advanced NSCLC To estimate the efficacy of nab-paclitaxel administered intravenously (IV) on Days 8 and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to 14 every 21 days or nab-paclitaxel ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

To determine the safety, clinical efficacy, and effect of azacitidine on the body,within the body and interactions within the body in children and young adults with newly diagnosed advanced Myelodysplastic Syndromes or Juvenile myelomonocyctic leukemia before transplantation of the bone marrow and blood. At the end of the study, the data will be compared to data from an older study of patients with the same diseases The primary objective is to assess the treatment effect on response rate (MDS: CR, PR, or marrow CR; JMML: either cCR or cPR) at Cycle 3 Day 28 and to compare against standard therapy using a matched-...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

AZA-ST-001 : Essai de phase 1 évaluant le CC-486 en monothérapie ou en association avec le carboplatine ou l’ABI-007, chez des patients ayant une tumeur solide en rechute ou réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer la tolérance et de déterminer la dose d’azacitidine orale à administrer en monothérapie ou en association avec le carboplatine ou l’ABI-007, chez des patients aya...

• Pays France
• Organes Tumeurs solides
• Spécialités Chimiothérapie

A study using a new drug (GED-0301) to investigate if the new drug works and is safe in subjects suffering ulcerative colitis To explore the effect of GED-0301 on clinical activity, as measured by the MMS in subjects with active UC.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to assess the safety and tolerability of durvalumab as monotherapy and in combination therapy in people with lymphoma or chronic lymphocytic leukemia Dose finding part (Phase 1): - To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2 placebo-controlled study to compare the effectiveness and safety of two doses of apremilast (CC-10004) in subjects with active rheumatoid arthritis, who have not responded to methotrexate treatment The primary objective is to evaluate the efficacy of two doses of apremilast (20 mg BID and 30 mg BID) compared with placebo on the reduction of signs and symptoms of RA at 24 weeks of treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 3 study of the safety and effectiveness of Apremilast versus placebo in patients with moderate to severe plaque psoriasis Studio di fase 3 per valutare l`efficacia e la sicurezza di Apremilast in pazienti affetti da psoriasi a placche moderata e grave Evaluate the clinical efficacy of apremilast 30 mg BID, compared with placebo, in subjects with moderate to severe plaque psoriasis Valutare l'efficacia clinica di apremilast 30 mg BID, rispett...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune